Opera Contract Research Organization S.r.l.
Timișoara, Timiș County, 300209, Romania
NCT Number: NCT03612986
Double blind, placebo controlled trial to evaluate the effects of a nutraceutical containing high-molecular-weight hyaluronic acid (HA) and acetyl-11-keto-beta-boswellicacid (AKBA) in patients affected by knee osteoarthritis.
Looking for future studies?
Notify Me45 year–70 year
All sexes
Interventional
Not applicable
Timișoara, Timiș County, 300209, Romania
The primary objective of the trial is to assess the feasibility of implementing Ultrasonography and Range of Motion (ROM) as objective measurements to correlate the improvement of the knee mobility with the pain reduction of the affected knee in the patients assuming nutraceutical containing hyaluronic acid (HA).
The secondary objectives of the trial are:
The explorative objectives of the trial are:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Reduction of pain and improvement of the knee mobility in patients affected by knee osteoarthritis
Placebo comparator. No chemical effect expected
Time frame: week 0, 4 and 16
Change in Visual Analogue Scale (VAS) results at rest, measured in mm
Time frame: week 0, 4 and 16
Change in Range of Motion (ROM) results, measured in grades by goniometer.
Time frame: week 0, 4 and 16
Change in Visual Analogue Scale (VAS) results at moving, measured in mm
Time frame: week 0, 4 and 16
Change in Visual Analogue Scale (VAS) results at pressing, measured in mm
Time frame: week 0 and 16
Change of presence or absence of Synovial fluid, Articular cartilage damage, Medial meniscal protrusion, Lateral meniscal protrusion, Medial osteophytes, Lateral osteophytes, Enthesopathies, Effusion is being assessed.
Time frame: week 0, 4 and 16
Change in parameters of quality of life will be assessed through Knee injury and Osteoarthritis Outcome Score (KOOS).
Time frame: week 0, 4 and 16
Change in parameters of quality of life will be assessed through Index of Severity for Osteoarthritis of the Knee by Lequesne et al.
Time frame: week 0 and 16
Knee movement based on acceleration results using an actimeter, device based on an accelerometer. The results will be measured in meter/second squared (m/s2) Change is being assessed.
Time frame: day 0, week 4 and 16
Adverse events (AE)/serious adverse events (SAE) (number of events occured, related to the investigational product administration)
Time frame: day 0, week 4 and 16
Safety assessed by the number of rescue medication tablets administered daily.
River Pharma S.r.l.
Other
Double Blind, Placebo Controlled Trial to Evaluate the Effects of a Nutraceutical Containing High-Molecular-Weight Hyaluronic Acid (HA) and Acetyl-11-Keto-Beta-Boswellic Acid (AKBA) in Patients Affected by Knee Osteoarthritis
Acronym: SMILE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07327190
Arthritis, Joint Diseases
Kütahya, Turkey (Türkiye)
View Trial DetailsNCT04492670
Arthritis, Joint Diseases
Hong Kong
View Trial DetailsNCT04653896
Arthritis, Joint Diseases
The Bronx, New York, United States
View Trial DetailsNCT07717957
Arthritis, Joint Diseases
Kuantan, Pahang, Malaysia
View Trial Details